These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 38865038)
21. [The EDQM Biological Standardisation Programme for the development of methods and reference preparations]. Buchheit KH; Seitz R Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1152-7. PubMed ID: 25112952 [TBL] [Abstract][Full Text] [Related]
22. Nanomedicine drug development: a scientific symposium entitled "Charting a roadmap to commercialization". Finch G; Havel H; Analoui M; Barton RW; Diwan AR; Hennessy M; Reddy V; Sadrieh N; Tamarkin L; Wolfgang M; Yerxa B; Zolnik B; Liu M AAPS J; 2014 Jul; 16(4):698-704. PubMed ID: 24821054 [TBL] [Abstract][Full Text] [Related]
23. Critical Care Network in the State of Qatar. Hijjeh M; Al Shaikh L; Alinier G; Selwood D; Malmstrom F; Hassan IF Qatar Med J; 2019; 2019(2):2. PubMed ID: 31763205 [TBL] [Abstract][Full Text] [Related]
24. Future perspectives for advancing regulatory science of nanotechnology-enabled health products. Halamoda-Kenzaoui B; Geertsma R; Pouw J; Prina-Mello A; Carrer M; Roesslein M; Sips A; Weltring KM; Spring K; Bremer-Hoffmann S Drug Deliv Transl Res; 2022 Sep; 12(9):2145-2156. PubMed ID: 35691982 [TBL] [Abstract][Full Text] [Related]
25. European Pharmacopoeia (EP), USDA and MAFF standards--will they ever be harmonised under the VICH umbrella? Castle P Dev Biol (Basel); 2005; 121():227-34. PubMed ID: 15962485 [TBL] [Abstract][Full Text] [Related]
26. Overview of the blood compatibility of nanomedicines: A trend analysis of in vitro and in vivo studies. Urbán P; Liptrott NJ; Bremer S Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 May; 11(3):e1546. PubMed ID: 30556649 [TBL] [Abstract][Full Text] [Related]
27. Sustaining Meaningful Patient Engagement Across the Lifecycle of Medicines: A Roadmap for Action. Cavaller-Bellaubi M; Faulkner SD; Teixeira B; Boudes M; Molero E; Brooke N; McKeaveney L; Southerton J; Vicente MJ; Bertelsen N; García-Burgos J; Pirard V; Reid K; Ferrer E Ther Innov Regul Sci; 2021 Sep; 55(5):936-953. PubMed ID: 33970465 [TBL] [Abstract][Full Text] [Related]
28. Procedures and methods of benefit assessments for medicines in Germany. Bekkering GE; Kleijnen J Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905 [TBL] [Abstract][Full Text] [Related]
29. The regulation of nanomaterials and nanomedicines for clinical application: current and future perspectives. Foulkes R; Man E; Thind J; Yeung S; Joy A; Hoskins C Biomater Sci; 2020 Sep; 8(17):4653-4664. PubMed ID: 32672255 [TBL] [Abstract][Full Text] [Related]
31. Production and characterisation of a candidate hyper-immune serum for the replacement of the Bordetella pertussis mouse antiserum Biological Reference Preparation. Morgeaux S; Bornstein N; Mourton-Gilles C; Chagnaud P; Charbonneau J; Maurin J; Daas A; Variot P; Behr-Gross ME Pharmeur Bio Sci Notes; 2020; 2020():141-160. PubMed ID: 32788037 [TBL] [Abstract][Full Text] [Related]
32. European coding system for tissues and cells: a challenge unmet? Reynolds M; Warwick RM; Poniatowski S; Trias E Cell Tissue Bank; 2010 Nov; 11(4):353-64. PubMed ID: 20617388 [TBL] [Abstract][Full Text] [Related]
33. Calibration of replacement international standard and European pharmacopoeia biological reference preparation for tetanus toxoid, adsorbed. Sesardic D; Winsnes R; Rigsby P; Tierney R; Gaines-Das R Biologicals; 2002 Mar; 30(1):49-68. PubMed ID: 11846430 [TBL] [Abstract][Full Text] [Related]
34. Survey of Clinical Translation of Cancer Nanomedicines-Lessons Learned from Successes and Failures. He H; Liu L; Morin EE; Liu M; Schwendeman A Acc Chem Res; 2019 Sep; 52(9):2445-2461. PubMed ID: 31424909 [TBL] [Abstract][Full Text] [Related]
35. ISO and CEN standards for health informatics--synergy or competition. Klein GO Stud Health Technol Inform; 2003; 96():259-65. PubMed ID: 15061554 [TBL] [Abstract][Full Text] [Related]
36. The European initiative on low-dose risk research: from the HLEG to MELODI. Belli M; Tabocchini MA; Jourdain JR; Salomaa S; Repussard J Radiat Prot Dosimetry; 2015 Sep; 166(1-4):178-81. PubMed ID: 25862536 [TBL] [Abstract][Full Text] [Related]
37. [Procedures and methods of benefit assessments for medicines in Germany]. Bekkering GE; Kleijnen J Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813 [TBL] [Abstract][Full Text] [Related]
38. Establishment of a candidate equine influenza Florida Clade 2 strain A/eq/Richmond/1/07 horse antiserum as Ph. Eur. Biological Reference Preparation/OIE International Reference Reagent. Paillot R; Regourd E; Behr-Gross ME Pharmeur Bio Sci Notes; 2020; 2020():125-140. PubMed ID: 32677612 [TBL] [Abstract][Full Text] [Related]
39. What Makes a Quality Health App-Developing a Global Research-Based Health App Quality Assessment Framework for CEN-ISO/TS 82304-2: Delphi Study. Hoogendoorn P; Versluis A; van Kampen S; McCay C; Leahy M; Bijlsma M; Bonacina S; Bonten T; Bonthuis MJ; Butterlin A; Cobbaert K; Duijnhoven T; Hallensleben C; Harrison S; Hastenteufel M; Holappa T; Kokx B; Morlion B; Pauli N; Ploeg F; Salmon M; Schnoor K; Sharp M; Sottile PA; Värri A; Williams P; Heidenreich G; Oughtibridge N; Stegwee R; Chavannes NH JMIR Form Res; 2023 Jan; 7():e43905. PubMed ID: 36538379 [TBL] [Abstract][Full Text] [Related]
40. [Development of alternative methods by the EDQM and the Biological Standardization Program]. Buchheit KH ALTEX; 2001; 18(1):19-22. PubMed ID: 11248845 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]